NICE guidance: Myeloma – diagnosis and management

These guidelines, produced by the National Institute for Health and Care Excellence (NICE), set out new recommendations for the diagnosis, treatment and care of myeloma patients with the aim of providing consistently excellent patient-focused care within the NHS in England.

 

 

NICE guidance on bortezomib and thalidomide for the first-line treatment of myeloma

Thalidomide with an alkylating agent and a corticosteroid is recommended as an option for the first-line treatment of non-transplant eligible myeloma patients in England. In addition, bortezomib with an alkylating agent and a corticosteroid is recommended as an option for first-line treatment of non-transplant eligible patients who are intolerant to or contraindicated to thalidomide.

 

AWMSG recommendations on the use of plerixafor

AWMSG has recommended the use of plerixafor (MozobilĀ®) as an option within NHS Wales in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells in myeloma patients whose cells mobilise poorly. Patients may use plerixafor if they have already failed one complete mobilisation attempt.

 

SMC advice on the use of bortezomib subcutaneous injection

SMC advice on the use of subcutaneous bortezomib injection within NHS Scotland in combination with melphalan and prednisone for the treatment of previously untreated non-transplant eligible myeloma patient or for the treatment of relapsed myeloma patients who have received at least one prior treatment and who have already undergone or are not transplant eligible.